COVID-19 Vaccines: Scientific Proof of Lethality.
Just over 12 months from deployment of the COVID 19 emergency use experimental vaccines, scientific studies in the thousands, and reports of criminal complaints of assault and murder from the illegal, unlawful use of biochemical poisons made to police forces around the country, verify an assault on an unsuspecting UK population. Irrefutable science shows that the COVID 19 vaccine is not safe and not effective in limiting transmission or infection from the SARS-CoV-2, coronavirus pathogens.
The “safe and effective” false propaganda, put out by public officials who now are continuing to push this vaccine, is a clear breach of duty. A public office holder is subject to, and aware of, a duty to prevent death or serious injury that arises only by virtue of the functions of the public office.
Many have breached that duty and, in doing so, are recklessly causing a risk of death or serious injury, by carrying on regardless of the now-confirmed dangers associated with COVID 19 injections. Some of these risks are blood clotting, myocarditis, pericarditis, thrombosis, thrombocytopenia, anaphylaxis, Bell’s palsy, Guillain-Barre, cancer including deaths, etc.
All of these are confirmed in the following science-and-government-gathered data from the UK Health and Security agency on COVID 19 regarding vaccine damage.
The term “vaccine” was changed recently to incorporate this illegal, unlawful medical experiment to facilitate usage of mRNA technology that is demonstrably not a vaccine, and which contains biologically toxic nano-metamaterials associated with 5G urban data gathering capability.
Metal nanoparticulates are known in science to be genotoxic—a poison that can also cause sterilization. The dangers posed to the victims in the near term from this medical battery are now known. However, the long term lethality of this weapon is not as yet realized due to the debilitating effects it has on the immune system, causing Acquired Immunodeficiency Syndrome(AIDS).
We can now confirm the 2017 depopulation defence-intelligence documents, showing the planned murder of over 55 million across the United Kingdom by 2025 using this biochemical weapon.
The Medicines and Healthcare (products) Regulatory Agency (MHRA) had prior warning of the expected large numbers of adverse reactions before the deployment—confirming the premeditated nature of the crime and public conduct offences then and now.
Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: elsevierhealth.com/action/cookieAbsent
Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulation and death after ChAdOx1 nCoV-19 vaccination: Vaccine-Induced Immune Thrombotic Thrombocytopenia with Disseminated Intravascular Coagulation and Death following the ChAdOx1 nCoV-19 Vaccine
Fatal cerebral hemorrhage after COVID-19 vaccine: Fatal cerebral haemorrhage after COVID-19 vaccine - PubMed
Myocarditis after mRNA vaccination against SARS-CoV-2, a case series: Myocarditis following mRNA vaccination against SARS-CoV-2, a case series
Three cases of acute venous thromboembolism in women after vaccination against COVID-19: Three cases of acute venous thromboembolism in females after vaccination for coronavirus disease 2019
Acute thrombosis of the coronary tree after vaccination against COVID-19: Acute Coronary Tree Thrombosis After Vaccination for COVID-19
US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020: US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 - PubMed
Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine: elsevierhealth.com/action/cookieAbsent
Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET): Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET) - PubMed
Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review: Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review
Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines
Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma: Covid-19 vaccine- induced thrombosis and thrombocytopenia-a commentary on an important and practical clinical dilemma
Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines
COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis: COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis
The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid): The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia
Roots of autoimmunity of thrombotic events after COVID-19 vaccination: Autoimmunity roots of the thrombotic events after COVID-19 vaccination
Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience: elsevierhealth.com/action/cookieAbsent
Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: nejm.org/action/cookieAbsent
Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in “23 male patients, including 22 previously healthy military members, myocarditis was identified within 4 days after receipt of the vaccine”: Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: nejm.org/action/cookieAbsent
Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children: Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children - PubMed
Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-19: nejm.org/action/cookieAbsent
Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19): Post-mortem findings in vaccine-induced thrombotic thombocytopenia | Haematologica
Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)
Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19 vaccination: Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination
Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old man. Aphasia seven days after second dose of an mRNA-based SARS-CoV-2 vaccine
Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines
Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination: Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination
Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis of European data: Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data
Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine: Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine
Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT)
Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers: Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers
“Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient with antiphospholipid syndrome”: “Portal vein thrombosis occurring after the first dose of mRNA SARS-CoV-2 vaccine in a patient with antiphospholipid syndrome”
Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination
Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination: Myocarditis, Pericarditis and Cardiomyopathy After COVID-19 Vaccination
Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection: Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection
Prothrombotic immune thrombocytopenia after COVID-19 vaccination: Prothrombotic immune thrombocytopenia after COVID-19 vaccination
Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story: Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success story
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin based anticoagulation: Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation
Thrombosis after COVID-19 vaccination: possible link to ACE pathways: Thrombosis post COVID-19 vaccinations: Potential link to ACE pathways
Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with adenovirus and after COVID-19: Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19
A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-19 vaccination: Middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination
Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination – A report of two UK cases
Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19): Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19).
Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw that breaks the camel’s back?: google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ
Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against the COVID-19 pandemic: What pathogenesis?: Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against COVID-19 pandemic: What pathogenesis?
Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the management of cerebral venous thrombosis related to COVID-19 vaccination: Recomendaciones diagnóstico-terapéuticas del grupo de trabajo de expertos de FACME ad-hoc sobre el manejo de la trombosis venosa cerebral relacionada con la vacunación frente a COVID-19
Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”: Thrombocytopenia and Intracranial Venous Sinus Thrombosis after "COVID-19 Vaccine AstraZeneca" Exposure - PubMed
Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination: Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination - PubMed
Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination: Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine - PubMed
Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine: nih.gov/pmc/articles/PMC7996471/
COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using data from VigiBase: Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase - PubMed
Cerebral venous thrombosis associated with the covid-19 vaccine in Germany: Error - Cookies Turned Off
Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event: Cerebral venous thrombosis post BNT162b2 mRNA SARS-CoV-2 vaccination: A black swan event - PubMed
The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination: The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination - PubMed
Thrombosis with thrombocytopenia after messenger RNA vaccine -1273: Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine - PubMed
Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data - PubMed
First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland - Nature Medicine
Exacerbation of immune thrombocytopenia after COVID-19 vaccination: Exacerbation of immune thrombocytopenia following COVID-19 vaccination - PubMed
First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine: First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination - PubMed
PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia: nejm.org/action/cookieAbsent
Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia: Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia - Nature
Myocarditis with COVID-19 mRNA vaccines: ahajournals.org/action/cookieAbsent
Myocarditis and pericarditis after COVID-19 vaccination: Myocarditis and Pericarditis After Vaccination for COVID-19
Myocarditis temporally associated with COVID-19 vaccination: ahajournals.org/action/cookieAbsent.
COVID-19 Vaccination Associated with Myocarditis in Adolescents: aappublications.org/…iatrics/early/2021/08/12/peds.2021-053427.full.pdf
Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19 - PubMed
Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature: Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review
COVID-19 vaccine-induced myocarditis: a case report with review of the literature: COVID-19 vaccine-induced myocarditis: Case report with literature review
Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings: Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings
Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent
Fulminant myocarditis and systemic hyper inflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients.
Acute myocarditis after administration of BNT162b2 vaccine: Acute myocarditis following administration of BNT162b2 vaccine
Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector: Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination
Myocarditis following vaccination with BNT162b2 in a healthy male: Myocarditis after BNT162b2 vaccination in a healthy male
Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2 infection: Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection
Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents: Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents
Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine: Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine
Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA: Acute Myocarditis Following mRNA-1273 SARS-CoV-2 Vaccination
Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection: Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection
Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age: Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age
Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man: Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man
Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents: Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents
A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2
Takotsubo cardiomyopathy after vaccination with mRNA COVID-19: Takotsubo Cardiomyopathy After mRNA COVID-19 Vaccination
COVID-19 mRNA vaccination and myocarditis: COVID-19 mRNA Vaccine and Myocarditis - PubMed
COVID-19 vaccine and myocarditis: COVID-19 Vaccine and Myocarditis - PubMed
Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study bvsalud.org/…oronavirus-2019-ncov/resourc e/en/covidwho-1360706.
COVID-19 vaccines and myocarditis: COVID-19 vaccines and myocarditis - PubMed
Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines lications-of-the-mrna-based-covid-19-vaccines Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines
Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination: Myocarditis, Pericarditis and Cardiomyopathy After COVID-19 Vaccination - PubMed
Myocarditis with covid-19 mRNA vaccines: ahajournals.org/action/cookieAbsent
Association of myocarditis with COVID-19 mRNA vaccine in children: jamanetwork.com/…ocarditis-with-mrna-co vid-19-vaccine-in-children/
Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children: Association of Myocarditis With BNT162b2 Vaccination in Children
Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S. military: Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines: Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines
Myocarditis following immunization with Covid-19 mRNA: nejm.org/action/cookieAbsent
Patients with acute myocarditis after vaccination withCOVID-19 mRNA: Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination
Myocarditis associated with vaccination with COVID-19 mRNA: rsna.org/action/cookieAbsent
Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination: Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination
Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series - Journal of Cardiovascular Magnetic Resonance
Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA: Clinical guidance for youth with myocarditis and pericarditis following mRNA COVID-19 Vaccination | Canadian Paediatric Society
Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination - PubMed
Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine: Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine
Myocarditis / pericarditis associated with COVID-19 vaccine: COVID-19 vaccine-associated myocarditis/pericarditis - Science.gc.ca
Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: Wolters Kluwer Health
Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine
The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism: The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism - PubMed
Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database: Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database - PubMed
Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination: Be Alert to the Risk of Adverse Cardiovascular Events after COVID-19 Vaccination
Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magnetic resonance imaging findings: ahajournals.org/action/cookieAbsent
In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine: ahajournals.org/action/cookieAbsent
Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?: Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? - PubMed
Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: nih.gov/pmc/articles/PMC8216855/
Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?: Myocarditis After SARS-CoV-2 Vaccination: A Vaccine-Induced Reaction? - PubMed
Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine: Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine - PubMed
Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report - PubMed
Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report: Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report - PubMed
Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis Insights From a Murine Model of Coronavirus Disease 2019 (COVID-19) mRNA Vaccination-Induced Myopericarditis: Could Accidental Intravenous Vaccine Injection Induce Myopericarditis?
Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination: Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination - PubMed
Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report: biomedcentral.com/articles/10.1186/s12872-021-02183
Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: Acute myocarditis after the second dose of SARS-CoV-2 vaccine: Serendipity or atypical causal relationship? - PubMed
Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine: COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis - PubMed
COVID-19 vaccine-induced rhabdomyolysis: case report with literature review: COVID-19 vaccine induced rhabdomyolysis: Case report with literature review - PubMed.
GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development: GM1 ganglioside antibody and COVID-19 related Guillain Barre Syndrome – A case report, systemic review and implication for vaccine development
Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature
Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association.
Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: Guillain-Barré Syndrome Presenting as Facial Diplegia after COVID-19 Vaccination: A Case Report
Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: Guillain-Barré syndrome following first injection of ChAdOx1 nCoV-19 vaccine: First report.
SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: SARS-CoV-2 vaccinations are unsafe for those experiencing post-vaccination Guillain-Barre syndrome
Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report: Post-COVID-19 vaccine acute hyperactive encephalopathy with dramatic response to methylprednisolone: A case report
Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database: Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database
Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence: Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence?.
New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination: New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine
Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association: Acute myelitis and ChAdOx1 nCoV-19 vaccine: Casual or causal association?
Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story: Bell's palsy and SARS-CoV-2 vaccines—an unfolding story
Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy: Bell’s Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy
Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine.
Bell’s palsy after COVID-19 vaccination: case report: Bell’s palsy following COVID-19 vaccination: a case report.
An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history: An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history
COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET: COVID-19 vaccine induced Axillary and Pectoral Lymphadenopathy on PET scan
ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine
Late cutaneous reactions after administration of COVID-19 mRNA vaccines: Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19
COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature: COVID-19 vaccine induced rhabdomyolysis: Case report with literature review
Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study
Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines.
COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee.
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:. Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation.
Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19
Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data:. Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data.
immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine:. Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine.
Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report: Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report.
COVID-19 RNA-based vaccines and the risk of prion disease: scivisionpub.com/…ovid19rna-based-vaccines-and-the-risk-of-prion-dis ease-1503.pdf
This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines: nejm.org/action/cookieAbsent.
Process-related impurities in the ChAdOx1 nCov-19 vaccine: Process-related impurities in the ChAdOx1 nCov-19 vaccine
COVID-19 mRNA vaccine causing CNS inflammation: a case series: COVID-19 mRNA vaccination leading to CNS inflammation: a case series - Journal of Neurology
Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine: Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - PubMed
Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol: Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol? - PubMed
Pfizer Vaccine Raises Allergy Concerns: Pfizer's vaccine raises allergy concerns - PubMed
Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020: Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020 - PubMed
Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021: Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021 - PubMed
Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021 - PubMed
Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021 - PubMed
Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: Immunization practices and risk of anaphylaxis: a current update, comprehensive of COVID-19 vaccination data - PubMed
Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration - PubMed
Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research: Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation - PubMed
Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA) - PubMed
Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines - PubMed
Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown: Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns - PubMed
Cutaneous adverse effects of available COVID-19 vaccines: Cutaneous adverse effects of the available COVID-19 vaccines - PubMed
Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report - PubMed
COVID-19 vaccines increase the risk of anaphylaxis: [COVID-19 vaccines increase the risk of anaphylaxis] - PubMed
Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine - PubMed
Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation: Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation - PubMed
Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine: Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine - PubMed
Acute allergic reactions to COVID-19 mRNA vaccines: Acute Allergic Reactions to mRNA COVID-19 Vaccines - PubMed
Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2: Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2 - PubMed
Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data - PubMed
Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience: Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health-care system experience - PubMed
Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI): tandfonline.com/action/cookieAbsent
.IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to mRNA COVID-19 vaccines - PubMed
Allergic reactions after COVID-19 vaccination: putting the risk in perspective: Allergic Reactions After COVID-19 Vaccination-Putting Risk Into Perspective - PubMed
Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study - PubMed 188.
Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts - PubMed
COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis - PubMed
Fatal brain hemorrhage after COVID-19 vaccine: Fatal cerebral haemorrhage after COVID-19 vaccine - PubMed
A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: A case series of cutaneous COVID-19 vaccine reactions at Loma Linda University Department of Dermatology - PubMed
Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases: Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases - PubMed
Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study - PubMed
Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases: Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases - PubMed
Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a review of 40 cases in an International Dermatology Registry - PubMed
Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome: COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome - PubMed
Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia - PubMed
Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: Intracerebral Hemorrhage due to Thrombosis with Thrombocytopenia Syndrome after Vaccination against COVID-19: the First Fatal Case in Korea - PubMed
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study - PubMed
Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review - PubMed.
Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials - PubMed.
A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine: A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration - PubMed
Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) - PubMed
Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: COVID-19 vaccine-associated acute cerebral venous thrombosis and pulmonary artery embolism - PubMed.
Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine: Thromboaspiration and fibrinolysis infusion for portomesenteric thrombosis after AstraZeneca COVID-19 vaccine administration - PubMed
59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine - PubMed
Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: A missed opportunity for a rapid return of experience - PubMed
Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines - PubMed
Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine: Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine - PubMed
Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern: Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination - PubMed
Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273: Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine - PubMed
Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination - PubMed
Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis: Insights from a murine model of COVID-19 mRNA vaccination-induced myopericarditis: Could accidental intravenous vaccine injection induce myopericarditis? - PubMed
Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine: Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine - PubMed
propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination: Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination - PubMed
Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report: Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination - A Case Report - PubMed
Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people - PubMed
COVID-19 vaccination association and facial nerve palsy: A case-control study: Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study - PubMed
The association between COVID-19 vaccination and Bell’s palsy: The association between COVID-19 vaccination and Bell's palsy - PubMed
Bell’s palsy after COVID-19 vaccination: Bell's palsy following COVID-19 vaccination - PubMed
Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine (AZD1222): Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222) - PubMed
Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine: Bell's Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine - PubMed
Sequential contralateral facial nerve palsy after first and second doses of COVID-19 vaccine: Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses - PubMed.
Transverse myelitis induced by SARS-CoV-2 vaccination: SARS-CoV-2 Vaccination-Induced Transverse Myelitis - PubMed
Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19): Peripheral Facial Nerve Palsy Following BNT162b2 (COVID-19) Vaccination - PubMed
Acute abducens nerve palsy after COVID-19 vaccination: Acute abducens nerve palsy following COVID-19 vaccination - PubMed.
Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-report database: Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database - PubMed
Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine: Transient Oculomotor Palsy Following the Administration of the Messenger RNA-1273 Vaccine for SARS-CoV-2 Diplopia Following the COVID-19 Vaccine - PubMed
Bell’s palsy after Ad26.COV2.S COVID-19 vaccination: Bell's palsy following the Ad26.COV2.S COVID-19 vaccination - PubMed
Bell’s palsy after COVID-19 vaccination: case report: Bell's palsy following COVID-19 vaccination: a case report - PubMed
A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination: A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine - PubMed
Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-19: [Guillian Barré syndromeafter mRNA-1273 vaccination against COVID-19] - PubMed
Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination: [Acute facial paresis as a possible complication of vaccination against SARS-CoV-2] - PubMed.
Bell’s palsy after COVID-19 vaccination with high antibody response in CSF: Bell's palsy following COVID-19 vaccination with high CSF antibody response - PubMed.
Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519: SARS-CoV-2 or SARS-CoV-2 vaccination associated Parsonage-Turner syndrome. Comment on: "Neuralgic amyotrophy and COVID-19 infection: 2 cases of spinal accessory nerve palsy" by Coll et al. Joint Bone Spine 2021;88:105196 - PubMed.
Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case report: Bell's palsy following a single dose of mRNA SARS-CoV-2 vaccine: a case report - PubMed.
Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19): causality or victim?: Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty? - PubMed
Autoimmune hepatitis triggered by vaccination against SARS-CoV-2: Autoimmune hepatitis triggered by SARS-CoV-2 vaccination - PubMed
Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity: Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity? - PubMed.
Autoimmune hepatitis after COVID vaccine: Auto-immune hepatitis following COVID vaccination - PubMed
A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19: A Novel Case of Bifacial Diplegia Variant of Guillain-Barré Syndrome Following Janssen COVID-19 Vaccination - PubMed
Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines - PubMed.
Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination - PubMed
Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: Diagnosis and Management of Cerebral Venous Sinus Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia - PubMed
Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19: Venous sinus thrombosis following vaccination with ChAdOx1 nCov-19 - PubMed
Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency - PubMed
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study - PubMed
Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data - PubMed
Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study - PubMed
First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland - PubMed
Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany - PubMed
Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia - PubMed
celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: Coeliac artery and splenic artery thrombosis complicated with splenic infarction 7 days following the first dose of Oxford vaccination, causal relationship or coincidence? - PubMed.
Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia: Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) - PubMed
Thrombocytopenia after COVID-19 vaccination: Thrombocytopenia after COVID-19 vaccination - PubMed.
Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination: Cerebral venous sinus thrombosis associated with thrombocytopenia post-vaccination for COVID-19 - PubMed.
Thrombosis with thrombocytopenia syndrome after COVID-19 immunization: Thrombosis with thrombocytopenia syndrome after COVID-19 vaccination - PubMed
Acute myocardial infarction within 24 hours after COVID-19 vaccination: Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination - PubMed.
Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: Bilateral Acute Macular Neuroretinopathy After Vaccination Against SARS-CoV-2 - PubMed
central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: Central Venous Sinus Thrombosis with Subarachnoid Hemorrhage Following an mRNA COVID-19 Vaccination: Are These Reports Merely Co-Incidental? - PubMed
Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: Intracerebral Hemorrhage due to Thrombosis with Thrombocytopenia Syndrome after Vaccination against COVID-19: the First Fatal Case in Korea - PubMed
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation - PubMed
Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine - PubMed
A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2 - PubMed
Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines - PubMed
Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: Acute Ischemic Stroke Revealing ChAdOx1 nCov-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia: Impact on Recanalization Strategy - PubMed
New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine: New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine - PubMed
Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines - PubMed
Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine - PubMed
Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine: Thromboaspiration and fibrinolysis infusion for portomesenteric thrombosis after AstraZeneca COVID-19 vaccine administration - PubMed.
Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia: Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia - PubMed
Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine: Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine - PubMed
Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination: Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia - PubMed.
Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series: Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series - PubMed.
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis - PubMed.
Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data from the French network of regional pharmacovigilance centers: Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres - PubMed.
Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: COVID-19 vaccine-associated acute cerebral venous thrombosis and pulmonary artery embolism - PubMed.
Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage: Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage - PubMed.
Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination: Thrombosis of the palmar digital vein after Oxford-AstraZeneca COVID-19 vaccination - PubMed.
Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination - PubMed
Cerebral venous thrombosis following COVID-19 vaccination: Cerebral Venous Thrombosis following COVID-19 Vaccination - PubMed.
Lipschütz ulcers after AstraZeneca COVID-19 vaccination: [Lipschütz Ulcers After the AstraZeneca COVID-19 Vaccine] - PubMed.
Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19: Amyotrophic neuralgia secondary to Vaxzevri (AstraZeneca) COVID-19 vaccine - PubMed
Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273: Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine - PubMed
Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19: [Intracerebral haemorrhage twelve days after vaccination with ChAdOx1 nCoV-19] - PubMed
Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism - PubMed
Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) - PubMed
Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites - PubMed
Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia: Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia - PubMed
Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: a report of an autoptic case and review of the literature - PubMed.
A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA: A Case of Acute Pulmonary Embolus after mRNA SARS-CoV-2 Immunization - PubMed
Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: Neurosurgical Considerations Regarding Decompressive Craniectomy for Intracerebral Hemorrhage after SARS-CoV-2-Vaccination in Vaccine Induced Thrombotic Thrombocytopenia-VITT - PubMed
Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia - PubMed.
Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine: Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine - PubMed.
Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia - PubMed.
Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature - PubMed.
Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine - PubMed.
Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination - PubMed.
Post-vaccinal encephalitis after ChAdOx1 nCov-19: Postvaccinal Encephalitis after ChAdOx1 nCov-19 - PubMed
Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence? - PubMed
Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma: Fatal Systemic Capillary Leak Syndrome after SARS-CoV-2Vaccination in Patient with Multiple Myeloma - PubMed
Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination - PubMed
Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome: Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Postvaccination ASIA Syndrome - PubMed.
Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine: Facial Diplegia: A Rare, Atypical Variant of Guillain-Barré Syndrome and Ad26.COV2.S Vaccine - PubMed
Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study - PubMed.
fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients - PubMed.
Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST): Reported adverse effects following COVID-19 vaccination at a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST) - PubMed
Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination: Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination - PubMed
Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine: Petechiae and Desquamation of Fingers Following Immunization With BTN162b2 Messenger RNA (mRNA) COVID-19 Vaccine - PubMed
Hepatitis C virus reactivation after COVID-19 vaccination: a case report: Hepatitis C Virus Reactivation Following COVID-19 Vaccination - A Case Report - PubMed
Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine: Bilateral Immune-Mediated Keratolysis After Immunization With SARS-CoV-2 Recombinant Viral Vector Vaccine - PubMed.
Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: Immune Thrombocytopenic Purpura Following Pfizer-BioNTech COVID-19 Vaccine in an Elderly Female - PubMed
Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine: Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with ChAdO×1 nCov-19 vaccine - PubMed
Reactive arthritis after COVID-19 vaccination: Reactive arthritis after COVID-19 vaccination - PubMed.
Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants: Two Cases of Graves' Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants - PubMed
Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient - PubMed
Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19: Generalized bullous fixed drug eruption after Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccination - PubMed
COVID-19 mRNA vaccine causing CNS inflammation: a case series: COVID-19 mRNA vaccination leading to CNS inflammation: a case series - PubMed
Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: Thymic hyperplasia after mRNA based Covid-19 vaccination - PubMed
Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination - PubMed
Tolosa-Hunt syndrome occurring after COVID-19 vaccination: Tolosa-Hunt Syndrome Presenting After COVID-19 Vaccination - PubMed
Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford-AstraZeneca) vaccination - PubMed
Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): Immune-Mediated Thrombocytopenia Associated With Ad26.COV2.S (Janssen; Johnson & Johnson) Vaccine - PubMed.
Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: Transient Thrombocytopenia With Glycoprotein-Specific Platelet Autoantibodies After Ad26.COV2.S Vaccination: A Case Report - PubMed.
Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: Post-COVID-19 vaccine acute hyperactive encephalopathy with dramatic response to methylprednisolone: A case report - PubMed
Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine - PubMed
Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine - PubMed
Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report - PubMed
Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination - PubMed
Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: Hemophagocytic lymphohistiocytosis following ChAdOx1 nCov-19 vaccination - PubMed.
IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19 - PubMed
A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: Leukocytoclastic Vasculitis After Vaccination With a SARS-CoV-2 Vaccine - PubMed.
Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca/Covishield): Report of two cases - PubMed
Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: Exacerbation of Hailey-Hailey Disease Following SARS-CoV-2 Vaccination - PubMed
Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up using ultrasonography - PubMed.
COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern on cases with underlying liver problem - PubMed.
Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: The International Cerebral Venous Thrombosis Consortium report on cerebral venous thrombosis following vaccination against SARS-CoV-2 - PubMed
Immune thrombocytopenia after vaccination during the COVID-19 pandemic: Immune thrombocytopenia following vaccination during the COVID-19 pandemic - PubMed
COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries: COVID-19: Lessons from Norway tragedy must be considered in vaccine rollout planning in least developed/developing countries - PubMed
Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: Rituximab-induced acute lympholysis and pancytopenia after COVID-19 vaccination - PubMed
Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: A report of two cases - PubMed
Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine: Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccination - PubMed.
Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature - PubMed
Vaccine-induced thrombocytopenia with severe headache: Vaccine-Induced Thrombocytopenia with Severe Headache - PubMed
Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine: Acute Perimyocarditis Following First Dose of mRNA Vaccine Against COVID-19 - PubMed
Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine: COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis - PubMed.
Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature - PubMed
Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2: Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination: Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination.
Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: Immune Thrombocytopenia Following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine - PubMed
Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration: nih.gov/pmc/articles/PMC8176657/.
Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine: elsevierhealth.com/action/cookieAbsent.
Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2: nih.gov/pmc/articles/PMC8014568/.
Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination: Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccine.
Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination: Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination | Blood Advances | American Society of Hematology
Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results
COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria: COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria | Blood | American Society of Hematology
Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany - PubMed.
Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: [Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management] - PubMed.
Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination - PubMed.
Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination - A report of two UK cases - PubMed.
Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: SARS-CoV-2 vaccine-induced cerebral venous thrombosis - PubMed.
Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: A Case Report - PubMed.
Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia - PubMed
The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia - PubMed
Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine - PubMed.
Cerebral venous thrombosis after COVID-19 vaccination: Cerebral Venous Thrombosis following COVID-19 Vaccination - PubMed
Lethal cerebral venous sinus thrombosis after COVID-19 vaccination: Fatal cerebral venous sinus thrombosis after COVID-19 vaccination - PubMed
Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19 - PubMed
Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular application of the vaccine? - PubMed.
Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: Central Venous Sinus Thrombosis with Subarachnoid Hemorrhage Following an mRNA COVID-19 Vaccination: Are These Reports Merely Co-Incidental? - PubMed
Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first cerebral MRI scan - PubMed
Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination - PubMed
Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19: Cerebral venous sinus thrombosis associated with thrombocytopenia post-vaccination for COVID-19 - PubMed.
Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine - PubMed.
Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series - PubMed.
Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome - PubMed.
Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study - PubMed
Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): Reported adverse effects following COVID-19 vaccination at a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST) - PubMed
Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency - PubMed
A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: Middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination - PubMed
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation - PubMed
Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study - PubMed
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis - PubMed
S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 - PubMed.
Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia - PubMed
Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: Acute Ischemic Stroke Revealing ChAdOx1 nCov-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia: Impact on Recanalization Strategy - PubMed
Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: Vaccine-induced immune thrombotic thrombocytopenia (VITT) - a novel clinico-pathological entity with heterogeneous clinical presentations - PubMed.
Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): Imaging and Hematologic Findings in Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 (AstraZeneca) Vaccination - PubMed
Autoimmunity roots of thrombotic events after vaccination with COVID-19: Autoimmunity roots of the thrombotic events after COVID-19 vaccination - PubMed
Cerebral venous sinus thrombosis after vaccination: the UK experience: Cerebral venous sinus thrombosis after vaccination: the UK experience - PubMed
Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: Massive cerebral venous thrombosis and venous watershed infarction as late complications of COVID-19: a case report - PubMed
Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: Australian and New Zealand approach to diagnosis and management of vaccine-induced immune thrombosis and thrombocytopenia - PubMed
An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination - PubMed
Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222) - PubMed.
A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine - PubMed
Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine - PubMed
Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine - PubMed
First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland - PubMed
ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107 720 doses of ChAdOx1 vaccination in Thailand - PubMed.
Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine - PubMed
Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: Neurosurgical Considerations Regarding Decompressive Craniectomy for Intracerebral Hemorrhage after SARS-CoV-2-Vaccination in Vaccine Induced Thrombotic Thrombocytopenia-VITT - PubMed
Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report: Large hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: A case report - PubMed
Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination - PubMed
A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: A Rare Case of Superior Ophthalmic Vein Thrombosis and Thrombocytopenia Following ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2 - PubMed
Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia - PubMed.
Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): Renal Vein Thrombosis and Pulmonary Embolism Secondary to Vaccine-induced Thrombotic Thrombocytopenia (VITT) - PubMed.
Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: Limb ischemia and pulmonary artery thrombosis after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine: a case of vaccine-induced immune thrombotic thrombocytopenia - PubMed.
Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study - PubMed.
Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: Secondary thrombocytopenia after SARS-CoV-2 vaccine: Report of a case of hemorrhage and hematoma after minor oral surgery - PubMed.
Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination - PubMed
Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels - PubMed
A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: casualty or causality? - PubMed.
Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia following ChAdOx1 nCOVID-19 vaccine in a pregnant woman - PubMed
Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia - PubMed
Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: Nephrotic Syndrome Following ChAdOx1 nCoV-19 Vaccine Against SARScoV-2 - PubMed.
A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis: A case of vaccine-induced immune thrombotic thrombocytopenia with massive artero-venous thrombosis - PubMed
Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination - PubMed
Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: Thrombocytopenia in a teen with sickle cell disease following COVID-19 vaccination - PubMed
Vaccine-induced thrombocytopenia with severe headache: Vaccine-Induced Thrombocytopenia with Severe Headache - PubMed
Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: medrxiv.org/content/10.1101/2021.08.30.21262866v1
COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis: medrxiv.org/content/10.1101/2021.09.13.21262182v1.
Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine: Error - Cookies Turned Off
Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model
A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: WITHDRAWN: A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products - PubMed
This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: nejm.org/action/cookieAbsent
Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: Bilateral uveitis after inoculation with COVID-19 vaccine: A case report
Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: medrxiv.org/content/10.1101/2021.08.30.21262866v1.
Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed
Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines - Cell Discovery
Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine: Lobar bleeding with ventricular rupture shortly after first dosage of an mRNA-based SARS-CoV-2 vaccine
Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution: ahajournals.org/action/cookieAbsent
ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome:science.org/action/cookieAbsent
Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US - PubMed
A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: - Abstract - Europe PMC.
VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: VITT after ChAdOx1 nCoV-19 Vaccination - PubMed
Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: Vaccine-induced immune thrombotic thrombocytopenia (VITT) - a novel clinico-pathological entity with heterogeneous clinical presentations - PubMed
Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: Treatment of ChAdOx1 nCoV-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia Related Acute Ischemic Stroke - PubMed
Spectrum of neurological complications after COVID-19 vaccination: Spectrum of neurological complications following COVID-19 vaccination - PubMed.
Cerebral venous sinus thrombosis after vaccination: the UK experience: Cerebral venous sinus thrombosis after vaccination: the UK experience - PubMed
Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: [Cerebral vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination] - PubMed
Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: Portal Vein Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) after Covid Vaccination with ChAdOx1 nCoV-19 - PubMed
Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination: Haematuria, a widespread petechial rash, and headaches following the Oxford AstraZeneca ChAdOx1 nCoV-19 Vaccination - PubMed
Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: Myocardial Infarction and Azygos Vein Thrombosis After ChAdOx1 nCoV-19 Vaccination in a Hemodialysis Patient - PubMed
Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination - PubMed
Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient - PubMed
Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: Guillain-Barré syndrome following ChAdOx1 nCoV-19 COVID-19 vaccination: A case series - PubMed
Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) managed with delayed therapeutic plasma exchange (TPE) - PubMed.
Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: Rare case of COVID-19 vaccine-associated intracranial haemorrhage with venous sinus thrombosis - PubMed.
Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis - PubMed.
Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis - PubMed.
Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score - PubMed
Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia - PubMed
In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: Hospital-based observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines - PubMed
Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccination: a report of three cases - PubMed
Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data - PubMed
Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More - PubMed
Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases - PubMed.
Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech - PubMed.
Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: Multiple Sites of Arterial Thrombosis in A 35-Year Old Patient after ChAdOx1 (AstraZeneca) Vaccination, Requiring Emergent Femoral and Carotid Surgical Thrombectomy - PubMed
Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: A case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital - PubMed
Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: Neuro-ophthalmic …